US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

N2OFF, Inc

1.01

-0.0600-5.61%

Volume:41.84K

Turnover:43.28K

Market Cap:2.80M

PE:-0.03

High:1.08

Open:1.05

Low:1.01

Close:1.07

52wk High:41.65

52wk Low:0.8756

Shares:2.77M

Float Shares:1.48M

Volume Ratio:0.47

T/O Rate:2.82%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-38.2406

EPS(LYR):-31.0892

ROE:-101.61%

ROA:-44.78%

PB:0.31

PE(LYR):-0.03

Loading ...

Overview Company News Filings

N2OFF highlights research on mitochondrial carriers in spaceflight conditions

MitoCareX Bio Advances Mitochondrial Drug Research Under N2OFF Inc

In Spaceflight Conditions: N2OFF‘s MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions

N2OFF: MitoCareX Bio Announces Positive In Vitro Results from Its Mitochondrial Carrier Small Molecule Platform

MitoCareX Bio Advances Mitochondrial Drug Discovery Under N2OFF Inc

N2OFF: MitoCareX Bio Spotlights Co-Founder's Pioneering Research on Mitochondrial Carriers in Spaceflight Stress Conditions

N2off Inc. Announces Unregistered Sale of Shares Under Regulation S

N2off Inc. Issues 35,000 Shares for Investor Relations Services

N2OFF Invests $340,000 to Boost Profit Stake in German Solar Project

N2OFF Advances German and Italian Renewable Projects with Key Regulatory Submissions

N2OFF Accelerates European Renewable Energy Momentum with Major De-Risking Milestones and Approximately $1.69 Million Value Unlock in Germany and Italy

N2off Inc. Held Annual Shareholder Meeting

N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination

N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers

N2off Inc. Files Initial Statement of Beneficial Ownership; Dr. Alon Silberman Reported as 10% Owner

N2off Inc. Discloses SciSparc Ltd. as 10% Owner in Initial Beneficial Ownership Filing

N2OFF Inc. Announces Date for Upcoming Annual Stockholders Meeting

SciSparc Closes Sale of MitoCareX to N2OFF

Scisparc Announces Closing of the Sale to N2off of Majority-Owned Subsidiary Mitocarex, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

THOMSON REUTERS

N2OFF Closes Merger with MitoCareX Bio

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NITO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NITO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NITO\",,,,,undefined,":{"symbol":"NITO","market":"US","secType":"STK","nameCN":"N2OFF, Inc","latestPrice":1.01,"timestamp":1770665711713,"preClose":1.07,"halted":0,"volume":41844,"delay":0,"changeRate":-0.056074766355140235,"floatShares":1484800,"shares":2772883,"eps":-38.24065,"marketStatus":"Trading","change":-0.06,"latestTime":"02-09 14:37:33 EST","open":1.05,"high":1.08,"low":1.01,"amount":43275.79707,"amplitude":0.065421,"askPrice":1.05,"askSize":35,"bidPrice":1.01,"bidSize":546,"shortable":3,"etf":0,"ttmEps":-38.24065,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770670800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":1.07,"preHourTrading":{"tag":"盘前","latestPrice":1.05,"preClose":1.07,"latestTime":"08:20 EST","volume":1265,"amount":1328.25,"timestamp":1770643250686,"change":-0.02,"changeRate":-0.018692,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.01,"preClose":1.07,"latestTime":"19:58 EST","volume":3597,"amount":3817.6467,"timestamp":1770425911563,"change":-0.06,"changeRate":-0.056075,"amplitude":0.074766},"volumeRatio":0.467682},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NITO\",,,,,undefined,":{"symbol":"NITO","floatShares":1484800,"roa":"-44.78%","roe":"-101.61%","lyrEps":-31.08924,"volumeRatio":0.467682,"shares":2772883,"dividePrice":0,"high":1.08,"amplitude":0.065421,"preClose":1.07,"low":1.01,"week52Low":0.87555,"pbRate":"0.31","psRate":"13.40","week52High":41.65,"institutionHeld":0,"latestPrice":1.01,"committee":0.879518,"eps":-38.24065,"divideRate":0,"volume":41844,"delay":0,"ttmEps":-38.24065,"open":1.05,"prevYearClose":1.68,"prevWeekClose":1.07,"prevMonthClose":1.26,"prevQuarterClose":1.68,"fiveDayClose":1.17,"twentyDayClose":1.695,"sixtyDayClose":3.27},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NITO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"NITO","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-8.29},{"market":"US","date":"2025-09-22","symbol":"NITO","defaultRemindTime":1758547800000,"type":"split","dateTimestamp":1758513600000,"forFactor":35,"toFactor":1,"ratio":35},{"market":"US","date":"2025-08-14","symbol":"NITO","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.18},{"market":"US","date":"2025-05-15","symbol":"NITO","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.39},{"date":"2025-03-31","symbol":"NITO","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743451200000,"name":null,"time":"Post Market","dateTimestamp":1743393600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NITO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NITO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NITO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NITO","date":"2026-02-06","current":-0.026412,"percent":0.779736,"low":-5.422858,"twenty":-1.173238,"median":-0.595693,"eighty":-0.371014,"high":-0.180382,"avg":-0.792132,"sd":0.598857,"marketCap":2555173},"quantilePoints":[{"date":"2024-03-22","current":-0.595253,"twenty":-0.631048,"median":-0.595253,"eighty":-0.565079,"marketCap":3680176},{"date":"2024-03-28","current":-0.621449,"twenty":-0.620493,"median":-0.616669,"eighty":-0.581791,"marketCap":3842137},{"date":"2024-04-05","current":-0.552817,"twenty":-0.616669,"median":-0.598957,"eighty":-0.58146,"marketCap":3605697},{"date":"2024-04-12","current":-0.613998,"twenty":-0.616669,"median":-0.595253,"eighty":-0.546534,"marketCap":4004746},{"date":"2024-04-19","current":-0.547695,"twenty":-0.620493,"median":-0.594426,"eighty":-0.545509,"marketCap":3572293},{"date":"2024-04-26","current":-0.494864,"twenty":-0.616669,"median":-0.578425,"eighty":-0.526939,"marketCap":3227706},{"date":"2024-05-03","current":-0.540685,"twenty":-0.616669,"median":-0.553624,"eighty":-0.526609,"marketCap":3526568},{"date":"2024-05-10","current":-0.471954,"twenty":-0.616135,"median":-0.544963,"eighty":-0.500326,"marketCap":3078275},{"date":"2024-05-17","current":-0.551831,"twenty":-0.611731,"median":-0.537689,"eighty":-0.487533,"marketCap":3078275},{"date":"2024-05-24","current":-0.552168,"twenty":-0.601179,"median":-0.544963,"eighty":-0.495771,"marketCap":3080153},{"date":"2024-05-31","current":-0.529753,"twenty":-0.595253,"median":-0.534692,"eighty":-0.4994,"marketCap":2955119},{"date":"2024-06-07","current":-0.413366,"twenty":-0.593598,"median":-0.528346,"eighty":-0.4857,"marketCap":2305879},{"date":"2024-06-14","current":-0.357786,"twenty":-0.593598,"median":-0.526939,"eighty":-0.471954,"marketCap":1995836},{"date":"2024-06-21","current":-0.435821,"twenty":-0.593213,"median":-0.526112,"eighty":-0.443796,"marketCap":2431135},{"date":"2024-06-28","current":-0.291534,"twenty":-0.592956,"median":-0.525021,"eighty":-0.438504,"marketCap":1626262},{"date":"2024-07-05","current":-0.299738,"twenty":-0.591462,"median":-0.521462,"eighty":-0.417453,"marketCap":1672029},{"date":"2024-07-12","current":-0.284748,"twenty":-0.589685,"median":-0.514583,"eighty":-0.401004,"marketCap":1588410},{"date":"2024-07-15","current":-0.299183,"twenty":-0.589334,"median":-0.512125,"eighty":-0.398685,"marketCap":1668932},{"date":"2024-08-02","current":-0.310163,"twenty":-0.587152,"median":-0.509667,"eighty":-0.38747,"marketCap":1730183},{"date":"2024-08-09","current":-0.217756,"twenty":-0.574533,"median":-0.506319,"eighty":-0.319688,"marketCap":1214707},{"date":"2024-08-16","current":-0.180382,"twenty":-0.558059,"median":-0.494864,"eighty":-0.299738,"marketCap":1020285},{"date":"2024-08-23","current":-0.221504,"twenty":-0.554108,"median":-0.471954,"eighty":-0.294618,"marketCap":1252877},{"date":"2024-08-30","current":-0.266467,"twenty":-0.552687,"median":-0.471954,"eighty":-0.284776,"marketCap":1507198},{"date":"2024-09-06","current":-0.217898,"twenty":-0.552168,"median":-0.444086,"eighty":-0.254768,"marketCap":1232481},{"date":"2024-09-13","current":-0.464429,"twenty":-0.551831,"median":-0.443724,"eighty":-0.250351,"marketCap":2626923},{"date":"2024-09-20","current":-0.370802,"twenty":-0.547695,"median":-0.438504,"eighty":-0.254768,"marketCap":2097344},{"date":"2024-09-27","current":-0.350275,"twenty":-0.544963,"median":-0.426783,"eighty":-0.266467,"marketCap":1981241},{"date":"2024-10-04","current":-0.327233,"twenty":-0.540685,"median":-0.415431,"eighty":-0.269557,"marketCap":1850906},{"date":"2024-10-11","current":-0.291344,"twenty":-0.534692,"median":-0.412501,"eighty":-0.284748,"marketCap":1647913},{"date":"2024-10-18","current":-0.297833,"twenty":-0.533812,"median":-0.398685,"eighty":-0.284748,"marketCap":1684616},{"date":"2024-10-25","current":-0.358089,"twenty":-0.529753,"median":-0.389851,"eighty":-0.284887,"marketCap":2025435},{"date":"2024-10-31","current":-0.353586,"twenty":-0.527502,"median":-0.384666,"eighty":-0.288773,"marketCap":1999967},{"date":"2024-11-08","current":-0.391267,"twenty":-0.526939,"median":-0.380765,"eighty":-0.290389,"marketCap":2213098},{"date":"2024-11-15","current":-0.371619,"twenty":-0.526939,"median":-0.382715,"eighty":-0.291185,"marketCap":2101964},{"date":"2024-11-22","current":-0.362082,"twenty":-0.526609,"median":-0.371619,"eighty":-0.291496,"marketCap":2010950},{"date":"2024-11-29","current":-0.416779,"twenty":-0.52603,"median":-0.380765,"eighty":-0.291976,"marketCap":2314731},{"date":"2024-12-06","current":-0.433829,"twenty":-0.524885,"median":-0.387205,"eighty":-0.293457,"marketCap":2409419},{"date":"2024-12-13","current":-0.427255,"twenty":-0.523151,"median":-0.391267,"eighty":-0.29481,"marketCap":2372913},{"date":"2024-12-20","current":-0.357416,"twenty":-0.521283,"median":-0.390966,"eighty":-0.295733,"marketCap":1985033},{"date":"2024-12-27","current":-0.539615,"twenty":-0.521641,"median":-0.391802,"eighty":-0.296475,"marketCap":2996943},{"date":"2025-01-03","current":-2.197901,"twenty":-0.523945,"median":-0.393979,"eighty":-0.297085,"marketCap":12206813},{"date":"2025-01-10","current":-3.779568,"twenty":-0.526939,"median":-0.395438,"eighty":-0.297271,"marketCap":20991156},{"date":"2025-01-17","current":-1.684373,"twenty":-0.533812,"median":-0.398685,"eighty":-0.297833,"marketCap":9354754},{"date":"2025-01-24","current":-2.403312,"twenty":-0.541541,"median":-0.401584,"eighty":-0.298913,"marketCap":13347637},{"date":"2025-01-31","current":-2.403312,"twenty":-0.552298,"median":-0.411963,"eighty":-0.299627,"marketCap":13347637},{"date":"2025-02-07","current":-2.280065,"twenty":-0.579414,"median":-0.413366,"eighty":-0.299738,"marketCap":12663143},{"date":"2025-02-14","current":-1.77311,"twenty":-0.593084,"median":-0.416531,"eighty":-0.301476,"marketCap":9847590},{"date":"2025-02-21","current":-1.476907,"twenty":-0.598216,"median":-0.417262,"eighty":-0.302088,"marketCap":8202522},{"date":"2025-02-28","current":-0.820618,"twenty":-0.616669,"median":-0.433623,"eighty":-0.30284,"marketCap":4557590},{"date":"2025-03-07","current":-0.616234,"twenty":-0.63141,"median":-0.43616,"eighty":-0.304035,"marketCap":3422471},{"date":"2025-03-14","current":-0.639445,"twenty":-0.63141,"median":-0.437918,"eighty":-0.307918,"marketCap":3551384},{"date":"2025-03-21","current":-0.612126,"twenty":-0.636828,"median":-0.442498,"eighty":-0.312459,"marketCap":3399654},{"date":"2025-03-28","current":-0.552556,"twenty":-0.631356,"median":-0.445095,"eighty":-0.314149,"marketCap":3068815},{"date":"2025-04-04","current":-0.754617,"twenty":-0.631356,"median":-0.451905,"eighty":-0.318148,"marketCap":3918728},{"date":"2025-04-11","current":-0.726148,"twenty":-0.645632,"median":-0.462175,"eighty":-0.321538,"marketCap":3770885},{"date":"2025-04-17","current":-0.740211,"twenty":-0.69088,"median":-0.467372,"eighty":-0.32281,"marketCap":3843916},{"date":"2025-04-25","current":-0.792691,"twenty":-0.722581,"median":-0.471954,"eighty":-0.324664,"marketCap":4116446},{"date":"2025-05-02","current":-0.801332,"twenty":-0.740623,"median":-0.476554,"eighty":-0.326306,"marketCap":4161316},{"date":"2025-05-09","current":-1.30343,"twenty":-0.754617,"median":-0.492796,"eighty":-0.327153,"marketCap":6768713},{"date":"2025-05-16","current":-1.644614,"twenty":-0.796602,"median":-0.504028,"eighty":-0.328769,"marketCap":8540480},{"date":"2025-05-23","current":-1.316449,"twenty":-0.814798,"median":-0.509516,"eighty":-0.331921,"marketCap":7394495},{"date":"2025-05-30","current":-1.219596,"twenty":-0.878118,"median":-0.510217,"eighty":-0.333298,"marketCap":6850471},{"date":"2025-06-06","current":-1.302344,"twenty":-1.18892,"median":-0.514583,"eighty":-0.334357,"marketCap":7315268},{"date":"2025-06-13","current":-1.314568,"twenty":-1.236566,"median":-0.520567,"eighty":-0.337057,"marketCap":7383931},{"date":"2025-06-20","current":-1.14296,"twenty":-1.236544,"median":-0.523349,"eighty":-0.337695,"marketCap":6420006},{"date":"2025-06-27","current":-1.147191,"twenty":-1.236522,"median":-0.526526,"eighty":-0.339681,"marketCap":6443774},{"date":"2025-07-03","current":-1.162237,"twenty":-1.231874,"median":-0.526939,"eighty":-0.340887,"marketCap":6528283},{"date":"2025-07-11","current":-1.165998,"twenty":-1.221819,"median":-0.530366,"eighty":-0.341757,"marketCap":6549410},{"date":"2025-07-18","current":-1.161766,"twenty":-1.197027,"median":-0.534692,"eighty":-0.343833,"marketCap":6525642},{"date":"2025-07-25","current":-1.577388,"twenty":-1.221819,"median":-0.542512,"eighty":-0.345694,"marketCap":8860189},{"date":"2025-08-01","current":-1.175138,"twenty":-1.231874,"median":-0.547695,"eighty":-0.348581,"marketCap":6600751},{"date":"2025-08-08","current":-1.177607,"twenty":-1.221819,"median":-0.552362,"eighty":-0.350063,"marketCap":6614618},{"date":"2025-08-15","current":-1.083793,"twenty":-1.216211,"median":-0.552817,"eighty":-0.351335,"marketCap":6087667},{"date":"2025-08-22","current":-0.764351,"twenty":-1.210439,"median":-0.560896,"eighty":-0.353189,"marketCap":7138272},{"date":"2025-08-29","current":-0.807212,"twenty":-1.197207,"median":-0.578425,"eighty":-0.35665,"marketCap":7538549},{"date":"2025-09-05","current":-0.762922,"twenty":-1.192514,"median":-0.589334,"eighty":-0.357638,"marketCap":7124929},{"date":"2025-09-12","current":-0.750064,"twenty":-1.189129,"median":-0.593277,"eighty":-0.357968,"marketCap":7004846},{"date":"2025-09-19","current":-0.573263,"twenty":-1.186058,"median":-0.593598,"eighty":-0.358415,"marketCap":5353704},{"date":"2025-09-26","current":-0.561271,"twenty":-1.182051,"median":-0.592022,"eighty":-0.359975,"marketCap":5241714},{"date":"2025-10-03","current":-0.422484,"twenty":-1.179467,"median":-0.583368,"eighty":-0.361597,"marketCap":3945581},{"date":"2025-10-10","current":-0.436771,"twenty":-1.178189,"median":-0.577816,"eighty":-0.366907,"marketCap":4079006},{"date":"2025-10-17","current":-0.411259,"twenty":-1.176422,"median":-0.569435,"eighty":-0.370531,"marketCap":3840747},{"date":"2025-10-24","current":-0.417382,"twenty":-1.175336,"median":-0.560118,"eighty":-0.370802,"marketCap":3897929},{"date":"2025-10-31","current":-0.349009,"twenty":-1.17445,"median":-0.553108,"eighty":-0.366907,"marketCap":3259393},{"date":"2025-11-07","current":-0.31023,"twenty":-1.173426,"median":-0.552659,"eighty":-0.357968,"marketCap":2897238},{"date":"2025-11-14","current":-0.320435,"twenty":-1.172486,"median":-0.551831,"eighty":-0.35207,"marketCap":2992542},{"date":"2025-11-21","current":-1.049068,"twenty":-1.17126,"median":-0.552659,"eighty":-0.35298,"marketCap":6972109},{"date":"2025-11-28","current":-1.240921,"twenty":-1.172674,"median":-0.552963,"eighty":-0.355118,"marketCap":8247164},{"date":"2025-12-05","current":-1.21643,"twenty":-1.175623,"median":-0.558966,"eighty":-0.357564,"marketCap":8084391},{"date":"2025-12-12","current":-1.249085,"twenty":-1.178497,"median":-0.566131,"eighty":-0.357907,"marketCap":8301421},{"date":"2025-12-19","current":-1.036822,"twenty":-1.178497,"median":-0.577206,"eighty":-0.358306,"marketCap":6890722},{"date":"2025-12-26","current":-0.930691,"twenty":-1.177642,"median":-0.581681,"eighty":-0.35908,"marketCap":6185373},{"date":"2026-01-02","current":-0.685772,"twenty":-1.177607,"median":-0.589334,"eighty":-0.36087,"marketCap":4557643},{"date":"2026-01-09","current":-0.685772,"twenty":-1.175632,"median":-0.593277,"eighty":-0.362082,"marketCap":4557643},{"date":"2026-01-16","current":-0.714346,"twenty":-1.17561,"median":-0.595253,"eighty":-0.370124,"marketCap":4747545},{"date":"2026-01-23","current":-0.764711,"twenty":-1.175232,"median":-0.595693,"eighty":-0.370666,"marketCap":5082268},{"date":"2026-01-30","current":-0.53234,"twenty":-1.17422,"median":-0.599187,"eighty":-0.370802,"marketCap":3537932},{"date":"2026-02-06","current":-0.384468,"twenty":-1.173238,"median":-0.595693,"eighty":-0.371014,"marketCap":2555173}],"updateTime":1770665853383},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NITO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608648108","title":"N2OFF highlights research on mitochondrial carriers in spaceflight conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2608648108","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608648108?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:20","pubTimestamp":1770038452,"startTime":"0","endTime":"0","summary":"N2OFF (NITO) highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio. The article,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/n2off-highlights-research-on-mitochondrial-carriers-in-spaceflight-conditions-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/n2off-highlights-research-on-mitochondrial-carriers-in-spaceflight-conditions-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NITO","BK4539","BK4093"],"gpt_icon":0},{"id":"2608861609","title":"MitoCareX Bio Advances Mitochondrial Drug Research Under N2OFF Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2608861609","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608861609?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:05","pubTimestamp":1770037513,"startTime":"0","endTime":"0","summary":"N2OFF, Inc.  has highlighted the work of its wholly-owned subsidiary, MitoCareX Bio Ltd., a specialty biotechnology company focused on developing small-molecule drugs that target human mitochondrial carriers. MitoCareX Bio utilizes proprietary approaches, including the MITOLINE algorithm, to model, screen, and validate compounds that target the SLC25A family of mitochondrial carriers. These efforts support the company's precision pipeline addressing conditions such as cancer, metabolic diseases, and rare inherited disorders linked to mitochondrial dysfunction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via GlobeNewswire  on February 02, 2026, and is solely r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL89LMYb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","LU0314104364.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4588","NDAQ","LU2210150020.SGD","BK4585","BK4539","BK4112","SG9999014013.SGD","IE00BGHQF748.EUR","SG9999014039.USD","NITO","BK4093","IE00BKPKM429.USD","SG9999014021.USD"],"gpt_icon":0},{"id":"2608862814","title":"In Spaceflight Conditions: N2OFF‘s MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2608862814","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608862814?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:05","pubTimestamp":1770037500,"startTime":"0","endTime":"0","summary":"Neve Yarak, Israel, Feb.  02, 2026  (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on theRTB (","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/02/3230243/0/en/In-Spaceflight-Conditions-N2OFF-s-MitoCareX-Bio-Highlights-Co-Founder-s-Innovative-Research-on-Mitochondrial-Carriers-in-Microgravity-and-Cosmic-radiation-Conditions.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4093","NITO"],"gpt_icon":0},{"id":"2605496573","title":"N2OFF: MitoCareX Bio Announces Positive In Vitro Results from Its Mitochondrial Carrier Small Molecule Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2605496573","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605496573?lang=en_us&edition=fundamental","pubTime":"2026-01-22 20:32","pubTimestamp":1769085120,"startTime":"0","endTime":"0","summary":"MITOLINE Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases – A Market Projected to Exceed $120 billion by 2030 Neve Y","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/22/3223650/0/en/N2OFF-MitoCareX-Bio-Announces-Positive-In-Vitro-Results-from-Its-Mitochondrial-Carrier-Small-Molecule-Platform.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NITO","BK4539","BK4093"],"gpt_icon":0},{"id":"2603398846","title":"MitoCareX Bio Advances Mitochondrial Drug Discovery Under N2OFF Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2603398846","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603398846?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:32","pubTimestamp":1768483933,"startTime":"0","endTime":"0","summary":"N2OFF Subsidiary MitoCareX Bio Highlights Research on Mitochondrial Carriers in Spaceflight Stress. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via GlobeNewswire  on January 15, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDLbj9vwJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NITO","IE00B3QW5Z07.USD","LU2095319765.USD","LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014021.USD","SG9999014039.USD","BK4585","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","BK4539","SG9999014005.SGD","BK4588","BK4093","IE00BKPKM429.USD","NDAQ"],"gpt_icon":0},{"id":"2603709988","title":"N2OFF: MitoCareX Bio Spotlights Co-Founder's Pioneering Research on Mitochondrial Carriers in Spaceflight Stress Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2603709988","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603709988?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:32","pubTimestamp":1768483920,"startTime":"0","endTime":"0","summary":"Neve Yarak, Israel, Jan.  15, 2026  (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/15/3219563/0/en/N2OFF-MitoCareX-Bio-Spotlights-Co-Founder-s-Pioneering-Research-on-Mitochondrial-Carriers-in-Spaceflight-Stress-Conditions.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NITO","BK4539","BK4093"],"gpt_icon":0},{"id":"2603630048","title":"N2off Inc. Announces Unregistered Sale of Shares Under Regulation S","url":"https://stock-news.laohu8.com/highlight/detail?id=2603630048","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603630048?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:06","pubTimestamp":1768338408,"startTime":"0","endTime":"0","summary":"N2off Inc. has announced the entry into a Securities Exchange Agreement with Voice Assist, Inc., and Save Foods Ltd., its majority-owned subsidiary. As part of this agreement, N2off will transfer its approximately 98% ownership stake in Save Foods to Voice Assist. The company disclosed that the shares of common stock involved in this transaction have been or will be issued in reliance upon the exemption from registration requirements under Regulation S of the Securities Act, characterizing the issuance as an unregistered sale of securities. The completion of the transaction is subject to customary closing conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL3KqC6m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NITO","BK4539","BK4093"],"gpt_icon":0},{"id":"2602154567","title":"N2off Inc. Issues 35,000 Shares for Investor Relations Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2602154567","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602154567?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:15","pubTimestamp":1768227350,"startTime":"0","endTime":"0","summary":"N2OFF, Inc. has issued 35,000 shares of common stock to a consultant as compensation for investor relations services. The shares were issued on January 8, 2026, in a transaction exempt from registration under Section 4 of the Securities Act of 1933, as it did not involve a public offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL9MDkYq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4093","BK4539","NITO"],"gpt_icon":0},{"id":"2601882045","title":"N2OFF Invests $340,000 to Boost Profit Stake in German Solar Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2601882045","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601882045?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:20","pubTimestamp":1767622810,"startTime":"0","endTime":"0","summary":"N2OFF Inc. has advanced its expansion in the European solar energy sector through a strategic partnership with Solterra Renewable Energy Ltd. The company made an advance payment of $340,000 to secure more favorable terms in its flagship German solar project, resulting in an estimated $1.7 million increase in project-level value. The project has reached the final stages of the permitting process and is on track for approval in Q3 2026. These moves reflect N2OFF’s focus on reducing regulatory risks, optimizing capital deployment, and enhancing monetization options in its European portfolio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via GlobeNewswire  on Janua","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL4WTfQ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU0314104364.USD","BK4585","SG9999014039.USD","IE00BGHQF748.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","BK4588","SG9999014013.SGD","BK4093","IE00BKPKM429.USD","NITO","LU2210150020.SGD","SG9999014005.SGD","SG9999014021.USD","BK4539","BK4112","LU2095319765.USD","NDAQ"],"gpt_icon":0},{"id":"2595738680","title":"N2OFF Advances German and Italian Renewable Projects with Key Regulatory Submissions","url":"https://stock-news.laohu8.com/highlight/detail?id=2595738680","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595738680?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:22","pubTimestamp":1767014532,"startTime":"0","endTime":"0","summary":"N2OFF Inc. has made significant progress in reducing permitting risks for its European renewable energy projects, particularly in Germany and Italy. In Germany, the company's flagship project is advancing through the regulatory process, having completed its first public consultation round with no objections or requested changes, indicating strong regulatory and community support. The final approval is anticipated in Q3 2026. In Italy, formal planning submissions for Sicilian battery storage projects were made in late November, marking a key milestone toward potential approvals in the second half of 2026. These developments enhance the visibility of regulatory approvals and position N2OFF for future value realization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL6BN9Hs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","NDAQ","SG9999014013.SGD","NITO","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4588","BK4093","SG9999014039.USD","LU0314104364.USD","LU2210150020.SGD","LU2095319765.USD","SG9999014021.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","BK4585","BK4539","BK4112"],"gpt_icon":0},{"id":"2595738940","title":"N2OFF Accelerates European Renewable Energy Momentum with Major De-Risking Milestones and Approximately $1.69 Million Value Unlock in Germany and Italy","url":"https://stock-news.laohu8.com/highlight/detail?id=2595738940","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595738940?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:22","pubTimestamp":1767014520,"startTime":"0","endTime":"0","summary":"Neve Yarak, Israel, Dec.  29, 2025  (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/29/3210909/0/en/N2OFF-Accelerates-European-Renewable-Energy-Momentum-with-Major-De-Risking-Milestones-and-Approximately-1-69-Million-Value-Unlock-in-Germany-and-Italy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","NITO","BK4093"],"gpt_icon":0},{"id":"2592937949","title":"N2off Inc. Held Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2592937949","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592937949?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:06","pubTimestamp":1765919181,"startTime":"0","endTime":"0","summary":"N2off Inc. held its annual general meeting of stockholders on December 16, 2025. Shareholders approved the re-election of directors to the board. An increase in shares available under the 2022 Share Incentive Plan was approved. The grant of shares to board members under this plan was also approved. The appointment of Somekh Chaikin, a member of KPMG International, as independent auditors for the fiscal year ended December 31, 2025, was ratified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 16, 2025, and is solely respon","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL2pSdW7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4093","NITO","BK4539"],"gpt_icon":0},{"id":"2584795376","title":"N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination","url":"https://stock-news.laohu8.com/highlight/detail?id=2584795376","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584795376?lang=en_us&edition=fundamental","pubTime":"2025-11-18 22:12","pubTimestamp":1763475120,"startTime":"0","endTime":"0","summary":"Neve Yarak, Israel, Nov.  18, 2025  (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, fol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/18/3190151/0/en/N2OFF-MitoCareX-Identifies-Hit-Compounds-and-Targets-Preclinical-Candidate-Nomination.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4093","NITO","BK4539"],"gpt_icon":0},{"id":"2579814048","title":"N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2579814048","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579814048?lang=en_us&edition=fundamental","pubTime":"2025-10-30 21:25","pubTimestamp":1761830700,"startTime":"0","endTime":"0","summary":"Neve Yarak, Israel, Oct.  30, 2025  (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) b","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177536/0/en/N2OFF-Completed-Merger-with-Cancer-Drug-Discovery-Company-Targeting-Tough-to-Treat-Pancreatic-and-Lung-Cancers.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4093","NITO","SPRC","BK4007","BK4139","BK4159","CAGR","BK4539"],"gpt_icon":0},{"id":"2579999403","title":"N2off Inc. Files Initial Statement of Beneficial Ownership; Dr. Alon Silberman Reported as 10% Owner","url":"https://stock-news.laohu8.com/highlight/detail?id=2579999403","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579999403?lang=en_us&edition=fundamental","pubTime":"2025-10-29 04:05","pubTimestamp":1761681951,"startTime":"0","endTime":"0","summary":"N2off Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing identifies Dr. Alon Silberman as a 10% owner of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL4ztTrQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","NITO","BK4093"],"gpt_icon":0},{"id":"2578354773","title":"N2off Inc. Discloses SciSparc Ltd. as 10% Owner in Initial Beneficial Ownership Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2578354773","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578354773?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:06","pubTimestamp":1761336369,"startTime":"0","endTime":"0","summary":"N2off Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing identifies SciSparc Ltd. as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL8zc9r6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","NITO","BK4139","BK4093","SPRC"],"gpt_icon":0},{"id":"2577192505","title":"N2OFF Inc. Announces Date for Upcoming Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2577192505","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577192505?lang=en_us&edition=fundamental","pubTime":"2025-10-24 21:01","pubTimestamp":1761310869,"startTime":"0","endTime":"0","summary":"N2OFF Inc. has scheduled its Annual Meeting of Stockholders for December 16, 2025. At the meeting, stockholders will be asked to vote on several resolutions, including the ratification of the appointment of Somekh Chaikin, a member of KPMG International, as the company's independent auditors for the fiscal year ended December 31, 2025, and the approval of the reincorporation of the company in the State of Israel. Other business matters may also be brought before the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL2tJmT7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4093","NITO","BK4539"],"gpt_icon":0},{"id":"2577535877","title":"SciSparc Closes Sale of MitoCareX to N2OFF","url":"https://stock-news.laohu8.com/highlight/detail?id=2577535877","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577535877?lang=en_us&edition=fundamental","pubTime":"2025-10-24 04:03","pubTimestamp":1761249790,"startTime":"0","endTime":"0","summary":"SciSparc Ltd. has completed the sale of its majority-owned subsidiary, MitoCareX Bio Ltd., to N2OFF, Inc. Under the terms of the agreement, N2OFF acquired 6,622 shares of MitoCareX from SciSparc for $700,000 and exchanged the remaining outstanding shares of MitoCareX with all sellers for shares of N2OFF's common stock, representing 40% of N2OFF's fully diluted capital stock. The sellers will also be entitled to 30% of N2OFF's financing proceeds, capped at $1.6 million, for five years following the closing date. Following the transaction, MitoCareX is now a wholly owned subsidiary of N2OFF, with its board reconstituted by N2OFF appointees. The agreement also includes milestone-based issuances of up to 25% of N2OFF's common stock, calculated on a fully diluted basis, to the sellers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL8vzwxp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2095319765.USD","BK4539","LU2210149790.SGD","NDAQ","IE00BKPKM429.USD","LU0314104364.USD","BK4093","IE00B3QW5Z07.USD","BK4112","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","NITO","SPRC","BK4007","IE00B64PRP62.GBP","BK4588"],"gpt_icon":0},{"id":"2577358445","title":"Scisparc Announces Closing of the Sale to N2off of Majority-Owned Subsidiary Mitocarex, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2577358445","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577358445?lang=en_us&edition=fundamental","pubTime":"2025-10-24 04:03","pubTimestamp":1761249780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUA1WRKW5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4093","NITO","SPRC","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2577535818","title":"N2OFF Closes Merger with MitoCareX Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2577535818","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577535818?lang=en_us&edition=fundamental","pubTime":"2025-10-24 04:02","pubTimestamp":1761249742,"startTime":"0","endTime":"0","summary":"N2OFF, Inc. has completed the acquisition of MitoCareX Bio Ltd., a biotech company focused on developing novel therapies for hard-to-treat cancers, including pancreatic and non-small cell lung cancer, by targeting the mitochondrial SLC25 protein family. As a result of the deal, MitoCareX has become a wholly-owned subsidiary of N2OFF. The transaction involved N2OFF purchasing ordinary shares of MitoCareX from SciSparc for $700,000 and issuing common stock to the sellers, representing 40% of N2OFF's fully diluted capital stock. The sellers are also entitled to a share of N2OFF's financing proceeds, capped at $1.6 million over five years, and may receive milestone-based issuances of up to 25% of N2OFF's common stock. The agreement includes a commitment by N2OFF to support MitoCareX's operations for the next two years.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL1nWB2m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","NITO","SPRC","BK4093","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":42,"code":"91000000","status":"200"}]}}